Company Filing History:
Years Active: 2010-2014
Title: The Innovations of Jean-Michel Itier
Introduction
Jean-Michel Itier is a notable inventor based in Savigny sur Orge, France. He has made significant contributions to the field of neuroscience through his innovative patents. With a total of 2 patents, Itier's work focuses on addressing critical health issues related to the central nervous system.
Latest Patents
Itier's latest patents include a method for identifying an antagonist of guanine nucleotide releasing factor 1. This invention utilizes whole or part of the GRF1 protein, or cells expressing this protein, to detect compounds that may prevent or treat pathologies involving neuronal death, such as apoptosis. The specific disorders targeted by this invention include cerebral ischemia, Parkinson's disease, and Alzheimer's disease. Another significant patent involves the development of nonhuman transgenic animals that exhibit major disorders related to Alzheimer's disease. These animals serve as valuable models for demonstrating compounds intended for the treatment of Alzheimer's disease.
Career Highlights
Jean-Michel Itier is associated with Aventis Pharma S.A., where he continues to contribute to groundbreaking research in the pharmaceutical industry. His work has implications for developing therapies that could improve the quality of life for individuals suffering from neurodegenerative diseases.
Collaborations
Itier has collaborated with notable colleagues, including Caty Casas Louzao and Patrick Benoit, enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Jean-Michel Itier's innovative work in the field of neuroscience highlights his commitment to addressing critical health challenges. His patents not only advance scientific understanding but also pave the way for potential treatments for debilitating diseases.